Table 6. Overview of Synergists Based on Clinically Used Antibiotics.

namea	ref	FICI	pathogen	antibiotic	hemolytic activityb
Tobramycin Derivatives
TOB-MOX 1	(291)	0.125	P. aeruginosa	novobiocin	<10% (30 min)
tobramycin-ciprofloxacin 1e	(292)	<0.04	P. aeruginosa	rifampicin	<10% (30 min)
tobramycin-rifampicin 1	(293)	0.28	P. aeruginosa	rifampicin	<10% (1 h)
tobramycin-rifampicin 2	(293)	0.15	P. aeruginosa	erythromycin	<10% (1 h)
tobramycin-rifampicin 3	(293)	0.06	P. aeruginosa	erythromycin	<10% (1 h)
tobramycin-lysine 3	(294)	0.008	P. aeruginosa	novobiocin	<10% (1 h)
TOB-NMP 1	(296)	≥0.008	P. aeruginosa	rifampicin	<10% (30 min)
TOB-PAR 2	(296)	≥0.008	P. aeruginosa	rifampicin	<10% (30 min)
tobramycin homodimer 1	(297)	0.07	P. aeruginosa	novobiocin	<10% (1 h)
tobramycin homodimer 2	(297)	0.08	P. aeruginosa	novobiocin	<10% (1 h)
tobramycin homodimer 3	(297)	0.05	P. aeruginosa	novobiocin	<10% (1 h)
tobramycin-cyclam 1	(298)	0.13	P. aeruginosa	novobiocin	<10% (30 min)
tobramycin-cyclam 2	(298)	0.13	P. aeruginosa	novobiocin	<10% (30 min)
tobramycin-cyclam 3	(298)	0.08	P. aeruginosa	novobiocin	<10% (30 min)
Nebramine Derivatives
NEB-MOX 1a	(299)	≥0.002	K. pneumoniae	rifampicin	NR
NEB-CIP 1b	(299)	≥0.008	P. aeruginosa	rifampicin	<10% (1 h)
NEB-NMP 2	(299)	≥0.004	P. aeruginosa	rifampicin	NR
nebramine-cyclam	(300)	0.25	P. aeruginosa	rifampicin	<10% (1 h)
Levofloxacin–Polybasic Peptide Conjugates
levofloxacin conjugate 10	(301)	0.10	P. aeruginosa	rifampicin	<10% (1 h)
levofloxacin conjugate 11	(301)	0.10	P. aeruginosa	novobiocin	<10% (1 h)
levofloxacin conjugate 12	(301)	0.08	P. aeruginosa	novobiocin	<10% (1 h)

^aCompound names are provided as given in the cited literature references.

^bNon-hemolytic is defined as <10% hemolysis compared to positive control, with incubation times denoted in parentheses; NR denotes no data reported.